TNI BioTech, a biotech company combating fatal diseases through the activation and mobilization of the body's immune system, announced this morning that it has entered an agreement with Pharmaceutical Care Consultants of South Florida, d/b/a Skip's Pharmacy. As a result of this agreement, Dr. Henry "Skip" Lenz and Phil Giordano will join the company as heads of Quality Control and Quality Assurance for its pharmaceutical plant in Managua, Nicaragua. Dr. Lenz will be responsible for spearheading the company's global manufacturing development.
Joining TNI BioTech's executive leadership team, Dr. Lenz will be responsible for making sure all manufacturing meets cGMP standards. Dr. Lenz has held senior management positions in quality control, quality assurance, and production for multiple international manufacturers. Furthermore, Dr. Lenz held senior clinical research pharmacist positions with both domestic and international clinical research groups, including Senior Researcher at Key Pharmaceuticals in charge of the Research Division. Dr. Lenz founded and ran a contract research company that secured over 10 patents before being acquired by a mid-sized manufacturing company. Over the last fifteen years, Dr. Lenz has concentrated his efforts on relieving HIV/AIDS by participating in clinical applications of several novel therapies.
Dr. Lenz is a graduate of The Massachusetts College of Pharmacy and the University of Florida. Currently, he owns Pharmaceutical Care Consultants of South Florida d/b/a Skip's Pharmacy in Boca Raton, Florida with his partner Phil Giordano. Skip's Pharmacy is dedicated to providing the highest quality and optimum pharmaceutical care through its unique ability to formulate and compound drugs specifically to meet patient's needs. Skip's Pharmacy has been the leading outlet for the supply of LDN for over ten years.
Noreen Griffin, TNI BioTech's CEO, underscored the company's unwavering dedication to delivering a quality product and becoming a world-class leader in innovative therapeutics for patients afflicted with autoimmune and infectious diseases such as cancer and HIV/AIDS.
Dr. Lenz stated, "I was pleased to see that TNIB was taking the manufacturing and distribution of IRT-103 (LDN) seriously. It is important that IRT-103 (LDN), a treatment that has done so much good for some any people, be available at a quality and a price that benefits everyone."
For additional information, visit the company's website at TNIBiotech.com
Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net